Gwen L. Nichols, MD
Patients with blood cancers face greater treatment costs than those with solid tumors. Furthermore, healthcare spending for these patients is already higher than average before diagnosis and does not return to prediagnosis levels even after successful treatment, according to a study commissioned by the Leukemia & Lymphoma Society (LLS).1
On average, per-patient spending in the first year after diagnosis topped 6,000, according to the Milliman research company, which conducted the study. The per-patient average ranged from nearly ,000 for chronic leukemia to more than 0,000 for acute leukemia (Figure
The figures in the report represent allowed spending, defined as costs paid by payers and patients combined, not including expenses not covered by insurance. Most of these costs are covered by payers, the report noted.
... to read the full story